Overview

* Kiniksa Q3 2025 ARCALYST revenue grows 61% yr/yr to $180.9 mln

* Company raises 2025 ARCALYST revenue guidance to $670-$675 mln

* KPL-387 granted Orphan Drug Designation for pericarditis treatment

Outlook

* Kiniksa raises 2025 ARCALYST revenue guidance to $670 mln - $675 mln

* Company expects to remain cash flow positive annually

* Data from KPL-387 Phase 2/3 trial expected in H2 2026

Result Drivers

* ARCALYST ADOPTION - Increased adoption of ARCALYST for recurrent pericarditis drove significant revenue growth

* REVENUE GUIDANCE RAISED - Kiniksa raised 2025 ARCALYST revenue guidance due to strong performance

* ORPHAN DRUG DESIGNATION - KPL-387 granted Orphan Drug Designation for pericarditis treatment

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $180.85

Product mln

Revenue

Q3 EPS $0.25

Q3 Net $18.43

Income mln

Q3 $156.83

Operatin mln

g

Expenses

Q3 $27.15

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Kiniksa Pharmaceuticals International PLC ( KNSA ) is $47.50, about 14.5% above its October 27 closing price of $40.60

* The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 29 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)